<SEC-DOCUMENT>0001745114-25-000022.txt : 20250612
<SEC-HEADER>0001745114-25-000022.hdr.sgml : 20250612
<ACCEPTANCE-DATETIME>20250612161701
ACCESSION NUMBER:		0001745114-25-000022
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250612
FILED AS OF DATE:		20250612
DATE AS OF CHANGE:		20250612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLECULAR PARTNERS AG
		CENTRAL INDEX KEY:			0001745114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40488
		FILM NUMBER:		251042637

	BUSINESS ADDRESS:	
		STREET 1:		WAGISTRASSE 14
		CITY:			Z?RICH-SCHLIEREN
		STATE:			V8
		ZIP:			8952
		BUSINESS PHONE:		41 44 755 77 00

	MAIL ADDRESS:	
		STREET 1:		WAGISTRASSE 14
		CITY:			Z?RICH-SCHLIEREN
		STATE:			V8
		ZIP:			8952
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>molecularpartners-form6xk_.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia3d6ecab8b9e4c69bb18abddec903a07_1"></div><div style="min-height:41.04pt;width:100%"><div style="padding-left:22.25pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Washington, D.C. 20549</font></div><div style="padding-left:198pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:139%">FORM 6-K</font></div><div style="padding-left:198pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PURSUANT TO RULE 13a-16 OR 15d-16</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">For the Month of June 2025</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Commission File Number&#58; 001-40488</font></div><div style="padding-left:198pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:139%">MOLECULAR PARTNERS AG</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(Exact name of registrant as specified in its charter)</font></div><div style="padding-left:198pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Wagistrasse 14</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:12.00pt">8952 Z&#252;rich-Schlieren</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Switzerland</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Telephone&#58; +41 447557700</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(Address of registrant&#8217;s principal executive offices)</font></div><div style="padding-left:198pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  Form 20-F    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  Form 40-F</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia3d6ecab8b9e4c69bb18abddec903a07_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXPLANATORY NOTE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:12.00pt">Molecular Partners AG (the &#34;Company&#34;) is filing this Form 6-K to furnish a press release the Company issued on June 10, 2025, which is furnished herewith as Exhibit 99.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:12.00pt">Exhibit 99.1 (excluding any quotes of&#160;management, website addresses or hyperlinks included therein) shall be deemed to be incorporated by reference into the registrant&#8217;s Registration Statements on Form F-3 (File No. 333-286488) and Form S-8 (File Nos. 333-272974 and 333-280491) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:12.00pt;text-decoration:underline">Exhibit</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">99.1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a href="a20250610molecularpartners.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">Press release issued June 10, 2025</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia3d6ecab8b9e4c69bb18abddec903a07_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">MOLECULAR PARTNERS AG</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(Registrant)</font></div><div style="padding-left:252pt;text-align:justify;text-indent:-243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58;  June 12, 2025&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">  &#47;s&#47; PATRICK AMSTUTZ&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Name&#58;  Patrick Amstutz</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Title&#58;  Chief Executive Officer </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20250610molecularpartners.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5c3fd25e011e4d1dacd735e4c1a19f2c_1"></div><div style="min-height:81.36pt;width:100%"><div style="text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:191px"><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:2.12pt;padding-right:2.12pt;text-align:center"><font><br></font></div><div style="padding-left:2.12pt;padding-right:2.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway </font></div><div style="padding-left:2.12pt;padding-right:2.12pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:4.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025</font></div><div style="padding-left:36pt;padding-right:4.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Cash reach now anticipated to extend into 2028</font></div><div style="padding-right:4.25pt"><font><br></font></div><div style="padding-right:4.25pt"><font><br></font></div><div style="padding-right:4.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zurich-Schlieren, Switzerland and Concord, Mass., June 10, 2025</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ad hoc announcement pursuant to Art. 53 LR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Molecular Partners</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> AG (SIX&#58; MOLN&#59; NASDAQ&#58; MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (&#8220;Molecular Partners&#8221; or the &#8220;Company&#8221;), today announces that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a result of this review the Company has informed the Amt f&#252;r Wirtschaft of Kanton Z&#252;rich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 40 positions, representing a potential of &#126;24% of all positions.</font></div><div style="padding-right:4.25pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;With strong data emerging from MP0533 and MP0712, our priority is to develop these assets which can provide most value for patients and shareholders. The plan to right-size the organization extends our cash reach into 2028, supporting both the development of our clinical assets and advancement of new products into the pipeline. We recognize the contribution that all of our talented employees have made to Molecular Partners and thank them as we take this difficult decision. The Board and I believe this is the right strategic path for the company to help secure its future success,&#34; said Patrick Amstutz, CEO of Molecular Partners.</font></div><div style="padding-right:4.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with Swiss employment law a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. This will include, but will not be limited to, severance packages, and support in seeking new employment, coaching or training opportunities. Molecular Partners foresees the full implementation of these changes enacted by the end of 2025 and the reduction of costs to become fully effective early in 2026.</font></div><div style="padding-right:4.25pt"><font><br></font></div><div style="padding-right:4.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result of these headcount reductions, the company now anticipates its cash runway to extend into 2028, beyond its prior guidance of 2027. The strategic review was undertaken to identify certain redundancies within the organization, with a focus on research and associated functions. The company will report its half-year financials on August 25, 2025.</font></div><div style="padding-right:4.25pt"><font><br></font></div><div style="padding-right:4.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Molecular Partners maintains its previously announced timelines with clinical data from both MP0533 and MP0712 expected in H2 2025.</font></div><div style="padding-right:4.25pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#231f20;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Molecular Partners AG</font><font style="background-color:#ffffff;color:#231f20;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Molecular Partners AG (SIX&#58; MOLN, NASDAQ&#58; MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:18.00pt">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:81.36pt;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%">clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%;text-decoration:underline">www.molecularpartners.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:130%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%">and find us on LinkedIn and Twitter &#47; X </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%;text-decoration:underline">&#64;MolecularPrtnrs</font></div><div style="margin-bottom:0.1pt"><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:145%">For further details, please contact&#58;</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Seth Lewis, SVP Investor Relations &#38; Strategy</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Concord, Massachusetts, U.S.</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">seth.lewis&#64;molecularpartners.com</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Tel&#58; +1 781 420 2361</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Laura Jeanbart, PhD, Head of Portfolio Management &#38; Communications </font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Zurich-Schlieren, Switzerland</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">laura.jeanbart&#64;molecularpartners.com </font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:145%">Tel&#58; +41 44 575 19 35</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Cautionary Note Regarding Forward-Looking Statements </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation&#58; implied and express statements regarding the clinical development of Molecular Partners&#8217; current or future product candidates&#59; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials&#59; the potential therapeutic and clinical benefits of Molecular Partners&#8217; product candidates and its RDT and Switch-DARPin platforms&#59; the selection and development of future programs&#59; Molecular Partners&#8217; collaboration with Orano Med including the benefits and results that may be achieved through the collaboration&#59; and Molecular Partners&#8217; expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as &#8220;aim&#8221;, &#34;anticipate&#8221;, &#8220;expect&#8221;, &#8220;guidance&#8221;, &#8220;intend&#8221;, &#8220;outlook&#8221;, &#8220;plan&#8221;, &#8220;potential&#8221;, &#8220;will&#8221; and similar expressions, and are based on Molecular Partners&#8217; current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners&#8217; expectations include its plans to develop and potentially commercialize its product candidates&#59; Molecular Partners&#8217; reliance on third party partners and collaborators over which it may not always have full control&#59; Molecular Partners&#8217; ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies&#59; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials&#59; the timing of and Molecular Partners&#8217; ability to obtain and maintain regulatory approvals for its product candidates&#59; the extent of clinical trials potentially required for Molecular Partners&#8217; product candidates&#59; the clinical utility and ability to achieve market acceptance of Molecular Partners&#8217; product candidates&#59; the potential that Molecular Partners&#8217; product candidates may exhibit serious adverse, undesirable or unacceptable side effects&#59; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners&#8217; preclinical studies, clinical trials or operations, or the operations of third parties on which it relies&#59; Molecular Partners&#8217; plans and development of any new indications for its product candidates&#59; Molecular Partners&#8217; commercialization, marketing and manufacturing capabilities and strategy&#59; Molecular Partners&#8217; intellectual property position&#59; Molecular Partners&#8217; ability to identify and in-license additional product candidates&#59; unanticipated factors in addition to the foregoing that may cause Molecular Partners&#8217; actual results to differ from its financial and business projections and guidance&#59; and other risks and </font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:81.36pt;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">uncertainties set forth in Molecular Partners&#8217; Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners&#8217; website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !K <T# 2(  A$! Q$!_\0
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M*OVIOVVOA?\ L7^%!J_Q'\7Z9X>252UM:.QEO;[':&! 9'YX)"[1GDBOA_\
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M\%Z38^+?&5I::UKD>A6=]-MN-4N8);F.VW'_ %DBQ@R,N>NT,WH#7Z-^"_\
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M/?'%_!J7B;6I=06[N(K:.V1Q#?W$*82,!1A(U' YQFOQ2_X.&_\ E*Y\0/\
MKSTG_P!-UO7ZY?\ !OE_RB;^&G_7?5__ $ZW=.O"*H1DEKI^0\/4D\3*+>FO
MYGVC7Y&?\%RO^"LGQN_8C_;)T[P?\._$FGZ3H-QX8M-3>&?2+:[8SR3W*,V^
M1&;!6-.,XX]Z_7.OY^_^#G[_ )2,:/\ ]B38?^E5[6.#BI5+21MCIRC2O%V/
MTA_X))_MM?$3]J__ ()P^+?B+XVU:UU+Q5I5_JL%M<Q6,-LB)!:Q21@QHH4X
M9B>1SWK\RO@W_P ' 7[4'C#XO^%=(O\ QGH\MCJNL6EG<(/#UBI>.2=$8 B/
M(R">17V[_P $!?\ E#AX^_["FN_^D,%?BA^SG_R<)X$_[&+3_P#TICKKHTH.
M4[K8XJ]::A3:;U/ZZJ***\H]D*X;]ICX^:+^R[\ _%?Q \02!-*\*Z=)?2)N
MPUPP&(X5_P!N1RB+[N*[FOQL_P"#H/\ ;<\ZX\-_ C0[S*Q;/$'B7RV[D$6E
MLWX;I64^L)K6C3YYJ)CB*OLZ;D?+FH_\'%W[4UYJ$\L/B_0[2&61G2!/#UDR
MPJ22$!:,L0!QDDGCDU][_P#!"/\ X+$>,/VTOB-XH^'OQ7U6PO\ Q1]G&JZ!
M=0V<-G]HA3Y;BW*QJJLRY21>,E3+GA17Q=_P17_X),VG[>OPN^+7B7Q+$8--
MATJ7P]X:N7!"Q:NZK+]IXZB "($?Q"<CM7R!\'_B5XN_83_:OTKQ!!;RZ;XN
M^'&N,MS9RDH?,A=HKBVDQ_"Z^9&V.S&O3G2I34H16J/(A6K4W&I-MIG]9]?G
M-_P<!_\ !0WXJ?L#V?PI?X9:W9Z,?%3ZLNH_:--@O/-$ L_*QYJMMQYTG3&<
M\]!7W?\  WXQ:+^T'\'O#7C?PY<"YT3Q3IT.HVCY&Y4D4-L8#HZG*L.S*1VK
M\HO^#LW_ )!OP'_ZZZ]_+3J\_#13JJ,D>GBYM47*+[?F?)7_ !$2_M5?]#OH
MW_A.6'_QJC_B(E_:J_Z'?1O_  G+#_XU7M?_  ;7_LD_#3]J)?C#_P +#\%:
M!XP_L4Z1]@_M.V$WV7S?MOF;,]-WEIG_ '17ZD_\.E?V:O\ HBO@'_P6K795
MJT82<7#\CAHT<14@IJ?XL_%KPU_P<>_M1:%JT5Q=>(O"^LPHP+6MYX?MTBD'
MH3"(W_)A7['?\$I_^"D%A_P4F_9YG\2G2X]"\3:!>?V;KFFQR&2&.4H'26)C
MSY4BDD!N5*NN3M#-^7'_  <A_L=_"?\ 95\7_"Z?X<>'-)\)W_B*VU :II^G
ML4B>.%K?R9C%DA"3),NX ;MO<K7MW_!I_;L/A_\ &N4H^Q]0TE Q'RDB.[)
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M6Y_4U;_%GPK=W"11>)= EEE8(B)J$+,[$X  #<DFOP,_X.9?^4DZ?]BGI_\
MZ,N*\1_9@_8'^.6@?M+?#N_OO@W\4K.RLO$VFSW%Q/X6OHXH(TNHF9V8Q850
M 22> !7U?_P<,_LF?%/XT_\ !01=9\'_  W\=^*M('AFQMS>Z1H-U>V_F*\Y
M9/,C1EW $9&<C(J*-*-*JO>OH:UZTJU%^[;5&'_P2L_X(5^$_P#@H/\ LJQ_
M$+6?'GB'P]>/JUUIWV2SLX98@L6S#9?G)W?I7TC_ ,0I7P^_Z*QXQ_\ !=;?
MXU^5$'[ ?[0MJFV+X-?%^->N%\+:@!_Z*I__  P7^T3_ -$=^,?_ (2^H_\
MQNMI1FW=5+'/"4%%)T[OYG[7_L-?\$ O!_[#/[37A_XFZ3\0O$FN7_A]+E([
M*[LH(X9?/MY(#EE.1@2$CW KY5_X.P;=U^)_P8E*D1OI>J(K=B1+;DC\,C\Z
M^+_V;?V'_C]HG[17@&\O_A+\6[2QM/$>G37$\_AJ_2*&-;J-F=V,> H ))/
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M9>*WT[3_ !7K&J:C%8V.AG5A9372L&:256$<AVH%Y.S&649!(SX1_P $SO\
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M<4URB!&G#%$VEU5,C!RP9LY8U^_7_#A;]D[_ *)-;_\ @^U3_P"2:XG]H_\
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M)'YEB;K_ %'DD'!&W[_O[5498*6U.7_@2_\ D2)_6HVYJD==/A?_ ,D>U_\
M#R'X5_\ 03U/_P %TO\ A2_\/(OA9_T$]4_\%TO^%>T?\(CI/_0,T[_P&3_"
MC_A$=)_Z!FG?^ R?X5/M<#_S[E_X$O\ Y$OV>,_GC_X"_P#Y(\6_X>0_"O\
MZ">I_P#@NE_PI?\ AY%\+/\ H)ZI_P""Z7_"O:/^$1TG_H&:=_X#)_A1_P (
MCI/_ $#-._\  9/\*/:8#_GW+_P)?_(A[/&?SQ_\!?\ \D>+_P##R+X6?]!/
M5/\ P72_X4?\/(OA9_T$]4_\%TO^%>T?\(CI/_0,T[_P&3_"C_A$=)_Z!FG?
M^ R?X4>TP'_/N7_@2_\ D0]GC/YX_P#@+_\ DCQ?_AY%\+/^@GJG_@NE_P *
M3_AY%\+/^@GJ?_@NE_PKVG_A$=)_Z!FG?^ R?X4?\(CI/_0,T[_P&3_"CVF
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M9_/'_P !?_R1XO\ \/(OA9_T$]4_\%TO^%)_P\B^%G_03U/_ ,%TO^%>T_\
M"(Z3_P! S3O_  &3_"C_ (1'2?\ H&:=_P" R?X4>UP/_/N7_@2_^1#V>,_G
MC_X"_P#Y(\6_X>0_"O\ Z"6I_P#@NE_PH_X>0_"O_H)ZG_X+I?\ "O:?^$1T
MG_H&:=_X#)_A1_PB.D_] S3O_ 9/\*/:X'_GW+_P)?\ R(>SQG\\?_ 7_P#)
M'BW_  \A^%?_ $$]3_\ !=+_ (4O_#R+X6?]!/5/_!=+_A7M'_"(Z3_T#-._
M\!D_PH_X1'2?^@9IW_@,G^%'M<#_ ,^Y?^!+_P"1#V>,_GC_ . O_P"2/%O^
M'D/PK/\ S$]3_P#!=+_A7H'P6_:'\,_'ZSOY_#5Q<W$>FND<YFMVA*E@2,;N
MO0UU/_"(Z3_T#-._\!D_PJQ8Z3:Z6K"VMK>W#\L(HPF[ZXK*M/"N#5*$D_.2
M:^ZR-*4,2I7J237DFOU9^$/_  =#_ &7P-^V)X7\?P0%=/\ '>A+;S2 <->6
M3>6^3_UQDML?0U^9-?TO?\%NOV*I?VTOV%M=LM(M#=>+?!S_ /"0Z(B+F2XD
MB5A+;KW)DA:0!>[B/TK^:$@@X/!%=N#J<U.W8\O'TN6JWT85_2M_P0G_ &IK
M3]IK_@G;X-A-PLFN> 81X6U.(MET^SJ!;L>^&MS$<]V#CL:_FIKZT_X(^_\
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M7E%WMTN;-T2MNY'!"DU^$7_!/K_@H'^U[^U9=>-OA;X \1W?B'QAK=Q#<_\
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M/^"O[>.[/_@G=\1M0^&VJZ[HWBW1K:WU.WNM'N9+>\2&"YBDN-CQD,/W"RY
MZ@$=Z^EZ1E#J00"#P0>]5&5FF3./-%Q/S8_X)5?\%N?A+J_[(_AK0OBO\2I-
M(^(>@126VJ7'B.6:1]3_ 'KLDZW)#"3*,H(9MP*D8Q@GZ6_X? ?LR_\ 19_!
M/_@6W_Q-3?%'_@D?^S;\8]:EU'7?A!X2:]G8O++812::96/5F^S-&&)[D\FN
M;3_@AO\ LJ1H%'P?TC XYU*_)_6>MY.BW?5?<<\8UXJVC^\H_'S_ (+5_LS?
M#_X5ZU>CXD>'O%<YLY4ATG2PU[/J#E"!#M"E0&/!+D+@\FOF3_@U;^&.N^'/
MV?\ XF^*KZWN(-$\3ZQ:6VF-(I5;AK6.;SI$SU7,R)N'&Z-AU4U]<>$O^"+G
M[+O@G6TU"R^#GAJ6XC.Y5OI;F_AS[Q3R/&?Q6OI3P[X<T_PCH=KIFE6-GIFF
MV,8AMK6UA6&&W0=%1% 55'H!BDZD%!PA?7N$:51U%.;6G8NT445SG45]6TFU
MU[3+BROK:"\L[N-H9X)XQ)',C##*RG(92"00>"*_+_\ ;\_X-I_!_P 8+V^\
M2_!;4K7P%KDY,LFA7@9]&N7//[IE!>VR>P#IT 5!7ZD45I3JR@[Q9E5HPJ*T
MT?RI?M.?\$X/C9^R#>W \=?#W7]/T^ G_B:VT/VS37'8BYBW1C(YPQ#>H%>(
M5_8VZ+(I# ,#P01G->-_%7_@GM\#/C5<RW'B?X3> =4O)CF2[;1H(KI\^LR*
MLA_[ZKNAF'\R/.GEG\DOO/Y2**_ICN/^"%?[*-U.TC?"'3@S')":QJ2+^ %P
M /PKIO ?_!(;]F?X;SK+IOP8\%3/'RIU*U;4\'Z7+25H\?"U[,R66U+[H_F>
M^%7P2\8_'3Q$FD^#/"WB#Q5J3D#[/I5A+=R+GNP0':/<X K]&_V)O^#9;XA?
M$Z\M-7^,NJP^ -!)#MI-C)'=ZQ<K_=+#=#!D=R9&'0H*_<;PIX+T;P'HT>G:
M'I.F:-I\/^KM;&U2WA3Z(@ 'Y5IUSU,=)Z15CJI9="+O-W/./V8?V2OA]^QS
M\-X?"OP\\-V7A_2TP\S1C?<7T@&/-GE;+RO[L3@<#  %>CT45Q-MN[/0225D
M%%%%(84444 <Q\9?@UX:_:"^&>K>#O&&EQZUX:UR-8KZR>62);A5=7 +(RL/
MF53P1TJE\ /V>/!O[+?PSM?!W@+1(O#WANREEF@LHYI9EC>1R[G=(S-RQ)Y-
M=I13N[6%RJ][:A1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
